292 related articles for article (PubMed ID: 27562490)
1. TERT promoter mutations and prognosis in solitary fibrous tumor.
Bahrami A; Lee S; Schaefer IM; Boland JM; Patton KT; Pounds S; Fletcher CD
Mod Pathol; 2016 Dec; 29(12):1511-1522. PubMed ID: 27562490
[TBL] [Abstract][Full Text] [Related]
2. Histological and molecular features of solitary fibrous tumor of the extremities: clinical correlation.
Bianchi G; Sambri A; Pedrini E; Pazzaglia L; Sangiorgi L; Ruengwanichayakun P; Donati D; Benassi MS; Righi A
Virchows Arch; 2020 Mar; 476(3):445-454. PubMed ID: 31463729
[TBL] [Abstract][Full Text] [Related]
3. Distinct clinicopathological features of NAB2-STAT6 fusion gene variants in solitary fibrous tumor with emphasis on the acquisition of highly malignant potential.
Akaike K; Kurisaki-Arakawa A; Hara K; Suehara Y; Takagi T; Mitani K; Kaneko K; Yao T; Saito T
Hum Pathol; 2015 Mar; 46(3):347-56. PubMed ID: 25582503
[TBL] [Abstract][Full Text] [Related]
4. TERT promoter mutations in solitary fibrous tumour.
Demicco EG; Wani K; Ingram D; Wagner M; Maki RG; Rizzo A; Meeker A; Lazar AJ; Wang WL
Histopathology; 2018 Nov; 73(5):843-851. PubMed ID: 29985536
[TBL] [Abstract][Full Text] [Related]
5. Telomerase promoter mutations and copy number alterations in solitary fibrous tumours.
Lin Y; Seger N; Tsagkozis P; Hesla AC; Ghaderi M; Chen Y; Ehnman M; Warsito D; Wejde J; Larsson O; Haglund F
J Clin Pathol; 2018 Sep; 71(9):832-839. PubMed ID: 29703757
[TBL] [Abstract][Full Text] [Related]
6. Solitary Fibrous Tumor: Integration of Clinical, Morphologic, Immunohistochemical and Molecular Findings in Risk Stratification and Classification May Better Predict Patient outcome.
Machado I; Nieto Morales MG; Cruz J; Lavernia J; Giner F; Navarro S; Ferrandez A; Llombart-Bosch A
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502329
[TBL] [Abstract][Full Text] [Related]
7. Solitary fibrous tumor: a case series identifying pathological adverse factors-implications for risk stratification and classification.
Machado I; Morales GN; Cruz J; Lavernia J; Giner F; Navarro S; Ferrandez A; Llombart-Bosch A
Virchows Arch; 2020 Apr; 476(4):597-607. PubMed ID: 31529158
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of NAB2-STAT6 fusion variants and TERT promotor mutations in solitary fibrous tumors/hemangiopericytomas of the CNS: not (yet) clear.
Vogels R; Macagno N; Griewank K; Groenen P; Verdijk M; Fonville J; Kusters B; ; ; Figarella-Branger D; Wesseling P; Bouvier C; Flucke U
Acta Neuropathol; 2019 Apr; 137(4):679-682. PubMed ID: 30761420
[No Abstract] [Full Text] [Related]
9. Determination of biological behavior of solitary fibrous tumors: correlation of expression of Ki-67, TPX2 and TERT mRNA subunit level and NAB2-STAT6 fusion compared to morphological aspects of SFTs.
Krsková L; Odintsov I; Fabián O; Hroudová P; Mrhalová M
Neoplasma; 2022 Jan; 69(1):28-35. PubMed ID: 34818026
[TBL] [Abstract][Full Text] [Related]
10. Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation.
Dagrada GP; Spagnuolo RD; Mauro V; Tamborini E; Cesana L; Gronchi A; Stacchiotti S; Pierotti MA; Negri T; Pilotti S
Mod Pathol; 2015 Aug; 28(8):1074-83. PubMed ID: 26022454
[TBL] [Abstract][Full Text] [Related]
11. Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup.
Pirker C; Bilecz A; Grusch M; Mohr T; Heidenreich B; Laszlo V; Stockhammer P; Lötsch-Gojo D; Gojo J; Gabler L; Spiegl-Kreinecker S; Dome B; Steindl A; Klikovits T; Hoda MA; Jakopovic M; Samarzija M; Mohorcic K; Kern I; Kiesel B; Brcic L; Oberndorfer F; Müllauer L; Klepetko W; Schmidt WM; Kumar R; Hegedus B; Berger W
Clin Cancer Res; 2020 Jul; 26(14):3819-3830. PubMed ID: 32317288
[TBL] [Abstract][Full Text] [Related]
12. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
13. Solitary fibrous tumor - clinicopathologic, immunohistochemical and molecular analysis of 28 cases.
Vogels RJ; Vlenterie M; Versleijen-Jonkers YM; Ruijter E; Bekers EM; Verdijk MA; Link MM; Bonenkamp JJ; van der Graaf WT; Slootweg PJ; Suurmeijer AJ; Groenen PJ; Flucke U
Diagn Pathol; 2014 Nov; 9():224. PubMed ID: 25432794
[TBL] [Abstract][Full Text] [Related]
14. Pathological prognostic markers in central nervous system solitary fibrous tumour/hemangiopericytoma: Evidence from a small series.
Bertero L; Anfossi V; Osella-Abate S; Disanto MG; Mantovani C; Zenga F; Rudà R; Garbossa D; Soffietti R; Ricardi U; Papotti M; Cassoni P
PLoS One; 2018; 13(9):e0203570. PubMed ID: 30183767
[TBL] [Abstract][Full Text] [Related]
15. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of a series of solitary fibrous tumors, including immunohistochemical expression of STAT6 and NATB2-STAT6 fusion transcripts, using Reverse Transcriptase(RT)-Polymerase chain reaction(PCR) technique: An Indian experience.
Rekhi B; Shetty O; Tripathi P; Bapat P; Ramadwar M; Bajpai J; Puri A
Pathol Res Pract; 2017 Nov; 213(11):1404-1411. PubMed ID: 28869107
[TBL] [Abstract][Full Text] [Related]
17. The clinicopathological significance of NAB2-STAT6 gene fusions in 52 cases of intrathoracic solitary fibrous tumors.
Huang SC; Li CF; Kao YC; Chuang IC; Tai HC; Tsai JW; Yu SC; Huang HY; Lan J; Yen SL; Lin PC; Chen TC
Cancer Med; 2016 Feb; 5(2):159-68. PubMed ID: 26686340
[TBL] [Abstract][Full Text] [Related]
18. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors.
Liu T; Brown TC; Juhlin CC; Andreasson A; Wang N; Bäckdahl M; Healy JM; Prasad ML; Korah R; Carling T; Xu D; Larsson C
Endocr Relat Cancer; 2014 Jun; 21(3):427-34. PubMed ID: 24803525
[TBL] [Abstract][Full Text] [Related]
19. TERT promoter mutation in adult granulosa cell tumor of the ovary.
Pilsworth JA; Cochrane DR; Xia Z; Aubert G; Färkkilä AEM; Horlings HM; Yanagida S; Yang W; Lim JLP; Wang YK; Bashashati A; Keul J; Wong A; Norris K; Brucker SY; Taran FA; Krämer B; Staebler A; van Meurs H; Oliva E; Shah SP; Kommoss S; Kommoss F; Gilks CB; Baird DM; Huntsman DG
Mod Pathol; 2018 Jul; 31(7):1107-1115. PubMed ID: 29449679
[TBL] [Abstract][Full Text] [Related]
20.
Tanaka A; Matsuse M; Saenko V; Nakao T; Yamanouchi K; Sakimura C; Yano H; Nishihara E; Hirokawa M; Suzuki K; Miyauchi A; Eguchi S; Yoshiura KI; Yamashita S; Nagayasu T; Mitsutake N
Thyroid; 2019 Aug; 29(8):1105-1114. PubMed ID: 31286848
[No Abstract] [Full Text] [Related]
[Next] [New Search]
